Therapeutic novelties in migraine: new drugs, new hope?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Therapeutic novelties in migraine : new drugs, new hope? / Do, Thien Phu; Guo, Song; Ashina, Messoud.

I: Journal of Headache and Pain, Bind 20, 37, 04.2019.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Do, TP, Guo, S & Ashina, M 2019, 'Therapeutic novelties in migraine: new drugs, new hope?', Journal of Headache and Pain, bind 20, 37. https://doi.org/10.1186/s10194-019-0974-3

APA

Do, T. P., Guo, S., & Ashina, M. (2019). Therapeutic novelties in migraine: new drugs, new hope? Journal of Headache and Pain, 20, [37]. https://doi.org/10.1186/s10194-019-0974-3

Vancouver

Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? Journal of Headache and Pain. 2019 apr.;20. 37. https://doi.org/10.1186/s10194-019-0974-3

Author

Do, Thien Phu ; Guo, Song ; Ashina, Messoud. / Therapeutic novelties in migraine : new drugs, new hope?. I: Journal of Headache and Pain. 2019 ; Bind 20.

Bibtex

@article{e0a863439eb6495ea2e446acaf3bd910,
title = "Therapeutic novelties in migraine: new drugs, new hope?",
abstract = "Background: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. Main body: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals. Conclusion: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.",
keywords = "Adverse event, Antibody, Ditan, Efficacy, Gepant, Migraine, Randomized clinical trial, Tolerability",
author = "Do, {Thien Phu} and Song Guo and Messoud Ashina",
year = "2019",
month = apr,
doi = "10.1186/s10194-019-0974-3",
language = "English",
volume = "20",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Therapeutic novelties in migraine

T2 - new drugs, new hope?

AU - Do, Thien Phu

AU - Guo, Song

AU - Ashina, Messoud

PY - 2019/4

Y1 - 2019/4

N2 - Background: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. Main body: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals. Conclusion: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.

AB - Background: In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies. Main body: The development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in the migraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals. Conclusion: Collectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.

KW - Adverse event

KW - Antibody

KW - Ditan

KW - Efficacy

KW - Gepant

KW - Migraine

KW - Randomized clinical trial

KW - Tolerability

U2 - 10.1186/s10194-019-0974-3

DO - 10.1186/s10194-019-0974-3

M3 - Review

C2 - 30995909

AN - SCOPUS:85064384769

VL - 20

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

M1 - 37

ER -

ID: 241204613